Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Targeting BRF2 in Cancer with Repurposed Drugs Using in Silico Methods

Version 1 : Received: 30 December 2020 / Approved: 31 December 2020 / Online: 31 December 2020 (08:49:33 CET)
Version 2 : Received: 16 July 2021 / Approved: 16 July 2021 / Online: 16 July 2021 (11:40:34 CEST)

A peer-reviewed article of this Preprint also exists.

{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T15:28:47Z","timestamp":1674660527717},"reference-count":86,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"The overexpression of BRF2, a selective subunit of RNA polymerase III, has been shown to be crucial in the development of several types of cancers, including breast cancer and lung squamous cell carcinoma. Predominantly, BRF2 acts as a central redox-sensing transcription factor (TF) and is involved in rescuing oxidative stress (OS)-induced apoptosis. Here, we showed a novel link between BRF2 and the DNA damage response. Due to the lack of BRF2-specific inhibitors, through virtual screening and molecular dynamics simulation, we identified potential drug candidates that interfere with BRF2-TATA-binding Protein (TBP)-DNA complex interactions based on binding energy, intermolecular, and torsional energy parameters. We experimentally tested bexarotene as a potential BRF2 inhibitor. We found that bexarotene (Bex) treatment resulted in a dramatic decline in oxidative stress and Tert-butylhydroquinone (tBHQ)-induced levels of BRF2 and consequently led to a decrease in the cellular proliferation of cancer cells which may in part be due to the drug pretreatment-induced reduction of ROS generated by the oxidizing agent. Our data thus provide the first experimental evidence that BRF2 is a novel player in the DNA damage response pathway and that bexarotene can be used as a potential inhibitor to treat cancers with the specific elevation of oxidative stress.<\/jats:p>","DOI":"10.3390\/cancers13153778","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T16:18:31Z","timestamp":1627402711000},"page":"3778","source":"Crossref","is-referenced-by-count":3,"title":["Targeting BRF2 in Cancer Using Repurposed Drugs"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"http:\/\/orcid.org\/0000-0002-9831-0319","authenticated-orcid":false,"given":"Behnam","family":"Rashidieh","sequence":"first","affiliation":[]},{"given":"Maryam","family":"Molakarimi","sequence":"additional","affiliation":[]},{"given":"Ammar","family":"Mohseni","sequence":"additional","affiliation":[]},{"given":"Simon Manuel","family":"Tria","sequence":"additional","affiliation":[]},{"given":"Hein","family":"Truong","sequence":"additional","affiliation":[]},{"given":"Sriganesh","family":"Srihari","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-3248-587X","authenticated-orcid":false,"given":"Rachael C.","family":"Adams","sequence":"additional","affiliation":[]},{"given":"Mathew","family":"Jones","sequence":"additional","affiliation":[]},{"given":"Pascal H. G.","family":"Duijf","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-0772-8673","authenticated-orcid":false,"given":"Murugan","family":"Kalimutho","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-8650-5381","authenticated-orcid":false,"given":"Kum Kum","family":"Khanna","sequence":"additional","affiliation":[]}],"member":"1968","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.11.005"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1039\/C5MB00655D"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0657-6"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000315"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208741"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0553-4"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/530786"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-47"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4161\/cc.2.3.375"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M201333200"},{"key":"ref11","series-title":"Ejb Reviews 1993","first-page":"29","article-title":"Rna polymerase iii","author":"Willis","year":"1994"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1018902"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0206"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1470"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.451"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-015-0033-4"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nature11935"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2203"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009843107"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14286-0"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19131"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ng1861"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.007"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.02.060"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4361"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15180"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0576-7"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.06.049"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.06.004"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3322"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0542"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3109\/02841861003614343"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2007.05.002"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.604"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-7-9"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7150\/jca.25587"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.034"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6861"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088309"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1028-7"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1037"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.21256"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/prot.10028"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.21334"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7150\/thno.22012"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28575"},{"key":"ref47","first-page":"3400","article-title":"Molecular dynamics simulation on the low sensitivity of mutants of NEDD-8 activating enzyme for MLN4924 inhibitor as a cancer drug","volume":"5","author":"Rashidieh","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149014"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1021\/ct9005745"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2017.01.012"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1534\/g3.117.041277"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(00)00387-3"},{"key":"ref53"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.12"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2009.01.006"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004826"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001040-00006"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07975.x"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061516-121357"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.9.7.3088"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4201"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1080\/10409230600648736"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.2174\/0929867053202197"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1728"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10452"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14432"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921649117"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2012.11.001"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2012.09.011"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.13.5989-5999.2004"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.2174\/092986708785132933"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.3.892"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00473-1"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg240"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.247"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01912-07"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.07.025"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/201367"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.344911"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/jat.1284"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.02.003"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3109\/10408441003601836"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011112-140320"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2019.4336"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/15\/3778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T15:22:13Z","timestamp":1627485733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/15\/3778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":86,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["cancers13153778"],"URL":"http:\/\/dx.doi.org\/10.3390\/cancers13153778","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202012.0770.v2","asserted-by":"object"},{"id-type":"doi","id":"10.20944\/preprints202012.0770.v1","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":["Cancer Research","Oncology"],"published":{"date-parts":[[2021,7,27]]}}} {"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T15:28:47Z","timestamp":1674660527717},"reference-count":86,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T00:00:00Z","timestamp":1627344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"The overexpression of BRF2, a selective subunit of RNA polymerase III, has been shown to be crucial in the development of several types of cancers, including breast cancer and lung squamous cell carcinoma. Predominantly, BRF2 acts as a central redox-sensing transcription factor (TF) and is involved in rescuing oxidative stress (OS)-induced apoptosis. Here, we showed a novel link between BRF2 and the DNA damage response. Due to the lack of BRF2-specific inhibitors, through virtual screening and molecular dynamics simulation, we identified potential drug candidates that interfere with BRF2-TATA-binding Protein (TBP)-DNA complex interactions based on binding energy, intermolecular, and torsional energy parameters. We experimentally tested bexarotene as a potential BRF2 inhibitor. We found that bexarotene (Bex) treatment resulted in a dramatic decline in oxidative stress and Tert-butylhydroquinone (tBHQ)-induced levels of BRF2 and consequently led to a decrease in the cellular proliferation of cancer cells which may in part be due to the drug pretreatment-induced reduction of ROS generated by the oxidizing agent. Our data thus provide the first experimental evidence that BRF2 is a novel player in the DNA damage response pathway and that bexarotene can be used as a potential inhibitor to treat cancers with the specific elevation of oxidative stress.","DOI":"10.3390\/cancers13153778","type":"journal-article","created":{"date-parts":[[2021,7,27]],"date-time":"2021-07-27T16:18:31Z","timestamp":1627402711000},"page":"3778","source":"Crossref","is-referenced-by-count":3,"title":["Targeting BRF2 in Cancer Using Repurposed Drugs"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"http:\/\/orcid.org\/0000-0002-9831-0319","authenticated-orcid":false,"given":"Behnam","family":"Rashidieh","sequence":"first","affiliation":[]},{"given":"Maryam","family":"Molakarimi","sequence":"additional","affiliation":[]},{"given":"Ammar","family":"Mohseni","sequence":"additional","affiliation":[]},{"given":"Simon Manuel","family":"Tria","sequence":"additional","affiliation":[]},{"given":"Hein","family":"Truong","sequence":"additional","affiliation":[]},{"given":"Sriganesh","family":"Srihari","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-3248-587X","authenticated-orcid":false,"given":"Rachael C.","family":"Adams","sequence":"additional","affiliation":[]},{"given":"Mathew","family":"Jones","sequence":"additional","affiliation":[]},{"given":"Pascal H. G.","family":"Duijf","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-0772-8673","authenticated-orcid":false,"given":"Murugan","family":"Kalimutho","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-8650-5381","authenticated-orcid":false,"given":"Kum Kum","family":"Khanna","sequence":"additional","affiliation":[]}],"member":"1968","published-online":{"date-parts":[[2021,7,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2015.11.005"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1039\/C5MB00655D"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-015-0657-6"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000315"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208741"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0553-4"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/530786"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-10-47"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.4161\/cc.2.3.375"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M201333200"},{"key":"ref11","series-title":"Ejb Reviews 1993","first-page":"29","article-title":"Rna polymerase iii","author":"Willis","year":"1994"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1018902"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0206"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1470"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.451"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-015-0033-4"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/nature11935"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2203"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009843107"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14286-0"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19131"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/ng1861"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2018.03.007"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.02.060"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4361"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms15180"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0576-7"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.06.049"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2013.06.004"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-3322"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0542"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3109\/02841861003614343"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2007.05.002"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.604"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-7-9"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.7150\/jca.25587"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.034"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.05.6861"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088309"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-1028-7"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1037"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.21256"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1002\/prot.10028"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1002\/jcc.21334"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7150\/thno.22012"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28575"},{"key":"ref47","first-page":"3400","article-title":"Molecular dynamics simulation on the low sensitivity of mutants of NEDD-8 activating enzyme for MLN4924 inhibitor as a cancer drug","volume":"5","author":"Rashidieh","year":"2015","journal-title":"Am. J. Cancer Res."},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0149014"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1021\/ct9005745"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.devcel.2017.01.012"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1534\/g3.117.041277"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(00)00387-3"},{"key":"ref53"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1038\/nature11412"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2014.12"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2009.01.006"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1004826"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200001040-00006"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.07975.x"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1111"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-061516-121357"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.9.7.3088"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4201"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1080\/10409230600648736"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.2174\/0929867053202197"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-1728"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10452"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14432"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1921649117"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2012.11.001"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagrm.2012.09.011"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.24.13.5989-5999.2004"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.2174\/092986708785132933"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.3.892"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00473-1"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg240"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.247"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01912-07"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.07.025"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.4061\/2010\/201367"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.344911"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1002\/jat.1284"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.02.003"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.3109\/10408441003601836"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-011112-140320"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2019.4336"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/15\/3778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T15:22:13Z","timestamp":1627485733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/15\/3778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,27]]},"references-count":86,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["cancers13153778"],"URL":"http:\/\/dx.doi.org\/10.3390\/cancers13153778","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202012.0770.v2","asserted-by":"object"},{"id-type":"doi","id":"10.20944\/preprints202012.0770.v1","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":["Cancer Research","Oncology"],"published":{"date-parts":[[2021,7,27]]}}}

DOI: 10.3390/cancers13153778

Abstract

Overexpression of BRF2, the essential subunit of RNA polymerase III, is required for the development of a variety of cancers, including lung squamous cell carcinoma and breast cancer. BRF2 also acts as a central redox-sensing transcription factor (TF) and is involved in the regulation of oxidative stress (OS) pathway where its amplification enables cancer cells to evade OS-induced apoptosis. Here, we experimentally confirmed a link between BRF2 and DNA damage response (DDR) signaling. Focusing on its DNA binding capacity, we targeted BRF2-TATA binding Protein (TBP)-DNA complex interaction to functionally inhibit this transcription factor (TF). We found that BRF2 binding to TBP changes the conformation of this protein and therefore characterized these events in detail. Virtual screening allowed selection of the optimal drug based on binding energy, and intermolecular, internal, and torsional energy parameters. Molecular dynamics simulation confirmed the docking results and all simulations were validated by root‐mean‐square deviation (RMSD). According to the simulation, the chosen drug was efficacious in targeting BRF2 which therefore requires further experimental validation to investigate the effect of this drug on BRF2 functions and its downstream pathways.

Keywords

BRF2; cancer; molecular dynamics simulation; drug repurposing; drug discovery

Subject

LIFE SCIENCES, Biochemistry

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.